Registering Italian medical devices and pharmaceuticals in Taiwan

Classification, pathway and the regulatory landscape

Medical devices are classified by risk level, and this classification is the first decision that matters. The risk level determines the regulatory pathway, the evidence required and the review process. Getting the classification right before submission is therefore the first task; changing it after submission costs time and sometimes requires starting again.

The regulatory authority in Taiwan for medical devices and pharmaceuticals sits within the Ministry of Health and Welfare. Separately, the national health insurance administration also under the Ministry of Health and Welfare handles reimbursement decisions. These are two distinct gates.

This guidance is general information only. A regulatory strategy for a specific product must be built in partnership with a Taiwanese regulatory adviser who understands the current requirements and the specific product characteristics. Regulatory frameworks evolve.

Device pathway determination by risk classification

Lower-risk devices follow a lighter regulatory pathway, typically requiring less extensive clinical or performance data. Higher-risk devices follow more demanding pathways and require more substantial evidence of safety and efficacy. The pathway determines what documentation must accompany the submission.

Documentation requirements scale with risk. A higher-risk device requires more comprehensive quality system documentation, clinical data, and evidence of manufacturing control. Understanding the full scope of what a given classification will demand is essential for budgeting time and resources.

The classification decision should be made early in partnership with the Taiwanese adviser, because it determines everything that follows.

The local licence holder and authorised representative

Taiwan's regulatory framework requires a local licence holder or authorised representative to hold the product registration. This is a legal requirement, not optional. The registration is held in the name of this local party, not in the name of the manufacturer.

This structure creates an immediate commercial consequence: the manufacturer does not own the Taiwanese registration. The product's market access depends on the continued relationship with the local licence holder or authorised representative. If that relationship terminates, the registration does not transfer to another party automatically; it would require a regulatory process to change the licence holder.

The distribution agreement and the regulatory licence-holder arrangement are separate. A distributor could also hold the registration, but the registration itself is a legal instrument that binds the manufacturer to the licence holder in ways that go beyond the contract terms. Before committing to any local partner, understand this dependency and structure the commercial terms accordingly. Refer to guidance on distribution and agency arrangements for contract structuring to protect your interests.

Manufacturing quality systems and inspection

Manufacturing sites are expected to operate quality management systems that meet international standards. The Taiwanese regulatory assessment includes either an on-site inspection of the manufacturing facility or a detailed documentary review, depending on the device class and the submission pathway.

The quality documentation must be thorough and available for inspection or review. This includes records of material sourcing, production processes, testing protocols, and traceability systems. Planning a Taiwanese submission requires ensuring that the manufacturing facility's documentation is audit-ready for Taiwanese requirements.

The inspection or documentary review is part of the approval timeline, not a step that occurs only after approval. Factor the manufacturing site's preparation and the regulatory authority's availability into the overall project schedule.

European approval evidence: supporting documents, not automatic recognition

Many European medical device manufacturers hold a CE certificate under the European Medical Device Regulation. Some also hold approval from European national regulatory bodies. These approvals demonstrate that the product meets European standards and have undergone European review. They are valuable evidence.

However, they are not automatically recognised as equivalent to Taiwanese approval. A Taiwanese submission must be built on Taiwanese terms, meeting Taiwanese requirements and providing evidence that satisfies Taiwanese regulators. The CE certificate and the technical file supporting it serve as background support for the submission, not as the basis of the case.

Approach the Taiwanese submission as a separate regulatory process from the outset. European approval evidence strengthens the submission, but do not assume that European approval will accelerate or substitute for Taiwanese approval.

Product labeling, instructions for use and Chinese language requirements

All product labeling must be in Chinese. Instructions for use must be provided in Chinese. This is not a translation of the European version; it is a distinct requirement that often involves reviewing the labeling for accuracy in the context of Taiwanese regulatory requirements.

Translation of technical specifications, warnings and instructions must be accurate and reviewed for technical meaning, not just linguistic correctness. The Chinese labeling will likely be reviewed by the regulatory authority as part of the approval process.

Budget time for translation, technical review and regulatory approval of the Chinese labeling. This is a separate workstream that should begin early, not at the end of the regulatory process.

Post-market obligations: vigilance, recalls and reporting

Once a product obtains regulatory approval, the licence holder incurs post-market obligations. Adverse events and product failures must be reported to the regulatory authority. These vigilance reports are required to continue, and non-reporting is a compliance violation.

If a product defect or safety issue emerges, the licence holder may be required to issue a market recall or withdrawal. Recalls must be reported to the authority and coordinated with distributors and users.

Compliance with post-market obligations is a condition of maintaining the registration. Non-compliance can result in suspension or cancellation of approval. The licence holder, whose name is on the registration, bears this responsibility.

Medicinal products: heavier requirements and imported finished goods

Medicinal products (pharmaceuticals) follow a more demanding regulatory pathway than devices. The evidence required includes not only manufacturing and quality data but also clinical trial data or clinical evidence of safety and efficacy in the intended population.

For imported finished pharmaceutical products, the regulatory assessment includes verification of the manufacturing site's inspection status. The authority will seek evidence that the site where the product is manufactured complies with current good manufacturing practices and has undergone inspection.

Imported finished goods require additional documentation about the source of manufacture and the manufacturing site's regulatory standing in its home country. This adds time and complexity to the submission for medicinal products beyond what is required for most medical devices.

Reimbursement under the national health insurance system: the second gate and the years ahead

Regulatory approval from the Ministry of Health and Welfare is necessary but not sufficient for commercial success in Taiwan. A second gate follows: reimbursement under the national health insurance system. A device or medicine that is approved but not reimbursed can be sold in the private market, but the reimbursed market is typically where volume and revenue occur.

Reimbursement is a separate application process on separate evidence. The authority considers not only the product's efficacy and safety (which were examined during regulatory approval) but also health economic data showing the product's value relative to existing alternatives, cost-effectiveness analysis, and comparative outcomes data. This evidence is not required for regulatory approval and must be built separately.

The reimbursement process often runs in parallel with or after regulatory approval, adding months to the pathway. Hospital procurement decisions and formulary inclusion depend on reimbursement status, so a product cannot rely on hospital sales until reimbursement is resolved.

The realistic timeline from initial submission to first meaningful revenue under reimbursement is measured in years rather than months. Many European companies underestimate this timeline and arrive in Taiwan expecting faster results. Build a business case that assumes years between initial submission and meaningful reimbursed revenue, and plan capital and resources accordingly.